Navigation Links
Surface Logix Appoints Keith Dionne as President and Chief Executive Officer
Date:10/14/2008

BOSTON, Oct. 14 /PRNewswire/ -- Surface Logix, a privately held biopharmaceutical company focused on using biophysical chemistry to create and develop novel small molecule drugs, is pleased to announce the appointment of Keith Dionne, Ph.D. to the position of President and Chief Executive Officer and to its Board of Directors. Dr. Dionne is a seasoned executive with nearly 20 years of leadership experience in the biotechnology industry.

"We are delighted to welcome Keith at this important stage of Surface Logix's development," stated Steven Gillis, Ph.D., Managing Director at ARCH Venture Partners and Chairman of Surface Logix. "We are confident that his proven track record and depth of experience will be instrumental as the Company continues to make progress on a number of fronts, including the further clinical development of two candidates in Phase 2 clinical trials."

Dr. Dionne was previously CEO of Alantos Pharmaceuticals, where he led the Company through a successful acquisition by Amgen for more than $300 million in cash. Prior to Alantos, Dr. Dionne held senior-level positions at Millennium Pharmaceuticals, including most recently Vice President of Research and Development Strategy and Vice President & General Manager: Technology Business. Before his 7-year tenure at Millennium, Dr. Dionne provided scientific leadership at ALZA Pharmaceuticals as Head of Pre-Clinical Research & Development: Implants.

"Surface Logix appealed to me because of its mature, differentiated pipeline, its exciting discovery capabilities and the strong team of discovery and development professionals," said Dr. Dionne. "I look forward to working with this team and our experienced Board and investors to fully realize the value of Surface Logix's late stage clinical assets and our discovery engine."

Dr. Dionne earned both his Ph.D. in Chemical Engineering and his M.S. in the Program for Technology Policy from the Massachusetts Institute of Technology and has served as an Adjunct Professor in the Biomedical Department at Brown University. Dr. Dionne was also one of four original scientists at CytoTherapeutics, Inc., a cell transplantation company.

About Surface Logix Inc.

Surface Logix Inc. uses its expertise in biophysical chemistry to create and develop novel small molecule drugs (NCEs) that target the gastrointestinal tract or the cardiovascular system. The Company is advancing multiple internal programs in the areas of metabolic, cardiovascular and other diseases. For more information, please visit http://www.surfacelogix.com.

Contact:

Leland Webster, Ph.D., M.B.A.

Surface Logix Inc.

Vice President, Corporate Development

617.746.8520

Media:

Sarah Cavanaugh

MacDougall Biomedical Communications Inc.

scavanaugh@macbiocom.com

781.235.3060


'/>"/>
SOURCE Surface Logix Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Killer pulses help characterize special surfaces
2. DARPA awards research team $1.2M grant to study surface enhanced Raman scattering
3. Trap and zap: Harnessing the power of light to pattern surfaces on the nanoscale
4. Surface Logix Announces Executive Management Changes
5. Surface dislocation nucleation: Strength is but skin deep at the nanoscale, Penn engineers discover
6. CaviWipes(R): Taking Surface Disinfection to a New Level
7. Arthrosurface Raises $4 Million of Preferred Equity Financing
8. Harland Medical Systems to Offer March Plasma Systems Surface Materials
9. Surface Logix Achieves Objectives With SLx-4090 in Phase 2a Clinical Trial
10. Decision Biomarkers Awarded U.S. Patent for Protein Array Surface Chemistry
11. Sureshield Coatings Company Established to Market Industry-Leading Portfolio of Advanced Coatings for Metal Surfaces
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/23/2017)... -- According to a report by Transparency Market Research ... to the presence of a large pool of participants; however, only ... and Sigma-Aldrich, compete with each other in this market. With Proliant ... 76% of this market in 2016.  ... As of now, a large number of vendors ...
(Date:3/23/2017)... (PRWEB) , ... March 23, 2017 , ... ... monitoring solutions, today announced the hire of Dr. Sigmund “Sig” Floyd as Vice ... applications, strategic partnerships and joint development activities. , “Dr. Floyd’s career has spanned ...
(Date:3/22/2017)...  Ascendis Pharma A/S (Nasdaq: ASND), a biopharmaceutical ... address significant unmet medical needs in rare diseases, ... ended December 31, 2016. "2016 ... we broadened our pipeline and pursued our vision ... with an initial focus on endocrinology," said ...
(Date:3/22/2017)... Oramed Pharmaceuticals Inc. (NASDAQ: ... ), a clinical-stage pharmaceutical company focused on ... today that Dr. Miriam Kidron , Oramed,s ... "Oral Insulin for Diabetes Treatment: Bypassing the Roadblock," ... Peptide Therapeutics (OPT) Boston Conference in Cambridge, ...
Breaking Biology Technology:
(Date:3/20/2017)... , March 20, 2017 PMD Healthcare ... personal spirometer and Wellness Management System (WMS), a remote, ... Founded in 2010, PMD Healthcare is a Medical Device, ... a mission dedicated to creating innovative solutions that empower ... With that intent focus, PMD developed the first ever ...
(Date:3/9/2017)... SAN FRANCISCO and MOUNTAIN VIEW, ... Zipongo , "Eating Well Made Simple," and 23andMe ... to help guide better food choices.  Zipongo can now ... only their food preferences, health goals and biometrics, but ... to certain food choices. Zipongo,s personalized food ...
(Date:3/2/2017)... 2017 Summary This report provides all ... partnering interests and activities since 2010. ... Read the full report: ... 2010 report provides an in-depth insight into the partnering activity ... On demand company reports are prepared upon purchase to ...
Breaking Biology News(10 mins):